Role of Bismuth in H. Pylori Treatment

Introduction to Bismuth-Based Therapies

Bismuth-containing quadruple therapy is recommended as first-line treatment for H. pylori eradication in areas of high clarithromycin resistance, as it overcomes antibiotic resistance and achieves superior eradication rates, according to the American Gastroenterological Association 1, 2

In areas of high clarithromycin resistance, bismuth-containing quadruple therapy is strongly recommended as first-line empirical treatment, as suggested by the European Society of Gastrointestinal Endoscopy 2, 3
Bismuth quadruple therapy typically consists of a PPI, bismuth salts, tetracycline, and metronidazole for 10-14 days, as recommended by the American College of Gastroenterology 3
This regimen avoids the issue of clarithromycin resistance and can achieve eradication rates >80%, according to the National Institute of Diabetes and Digestive and Kidney Diseases 4, 3

In patients with penicillin allergy in areas of high clarithromycin resistance, bismuth-containing quadruple therapy should be preferred, as suggested by the British Society of Gastroenterology 5
When bismuth is not available, alternative regimens such as sequential or non-bismuth quadruple therapy (concomitant) may be considered, according to the World Gastroenterology Organisation 2

Success of H. pylori eradication should be confirmed at least 4 weeks after completing treatment, as recommended by the European Helicobacter Study Group 2, 5
The urea breath test (UBT) or a validated monoclonal stool test are recommended for confirming eradication, according to the American Gastroenterological Association 2, 5

14-day bismuth quadruple therapy is recommended by most guidelines, though 10-day regimens may be acceptable if proven locally effective, as suggested by the American College of Gastroenterology 3
Despite the number of pills required, studies show satisfactory compliance with bismuth-containing regimens, according to the European Society of Gastrointestinal Endoscopy 2